Streetbeat News

Products Services

ABOS

Acumen Pharmaceuticals presented positive results from the Phase 1 INTERCEPT-AD study of sabirnetug for early Alzheimer's at the AD/PD 2024 Annual Meeting. The cerebrospinal fluid biomarker results support sabirnetug's effects in the brain. A novel assay was showcased for assessing sabirnetug's binding to amyloid beta oligomers. Acumen is set to begin a Phase 2 trial and a Phase 1 subcutaneous study in 2024.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 1:57 pm

CURLF

Amsterdam will not participate in the Netherlands' legal cannabis trial, aimed at regulating and monitoring coffee shops. The trial, started in December 2023, allows legal operation across 10 municipalities but faced opposition. Italy launches a project to develop hemp supply chains in Sicily, funded by the EU and Sicilian Region. In the UK, cannabis clinics report an increase in ADHD patients due to medication shortages, with Curaleaf's research director commenting on the trend.

Portfolio Pulse from Nina Zdinjak

March 08, 2024 | 1:53 pm

ABOS

Acumen Pharmaceuticals shares surged following the presentation of biomarker data from the ACU193 Phase 1 INTERCEPT-AD trial at the International Conference on Alzheimer's and Parkinson's Diseases.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 1:52 pm

AMLX

GRFS

WLDN

Willdan Group (WLDN) shares surged 21% after reporting better-than-expected Q4 results and issuing strong FY24 guidance, alongside securing a $30-50 million contract. Grifols (GRFS) shares rose 20%, stating recent integration has no significant financial impact. Amylyx Pharmaceuticals (AMLX) plummeted 81% as its Phase 3 trial for AMX0035 in ALS failed to meet primary or secondary endpoints.

Portfolio Pulse from ryanfaloona@benzinga.com

March 08, 2024 | 1:44 pm

AAPL

Apple Inc. is reportedly adding new accessibility features to its upcoming iOS 18 and macOS 15 updates, aiming to enhance inclusivity and user-friendliness. These features include Adaptive Voice Shortcuts, an upgraded Live Speech function, expanded adjustable Text Size, and potentially an on-device eye-tracking feature. The updates are part of Apple's strategy to improve software quality and integrate generative AI capabilities, with more details expected at WWDC 2024.

Portfolio Pulse from Benzinga Neuro

March 08, 2024 | 1:43 pm

AVGO

GOOG

META

MRVL

Broadcom Inc (NASDAQ:AVGO) and Marvell Technology Inc (NASDAQ:MRVL) experienced stock dips despite high expectations in the AI chip sector. Broadcom's unchanged $50 billion annual revenue forecast and Marvell's lower-than-expected revenue forecast led to declines in their stock prices after-hours. Both companies are highlighted for their potential in the AI market, with Broadcom expecting $10 billion in AI-related revenue. Marvell announced a $3 billion share repurchase program. Broadcom's AI revenue is partly attributed to custom chip designs for major clients speculated to be Alphabet Inc's Google and Meta Platforms Inc.

Portfolio Pulse from Anusuya Lahiri

March 08, 2024 | 1:18 pm

COIN

PLTR

TSLA

Cryptocurrencies like Bitcoin, Ethereum, and Dogecoin have seen significant spikes, with Bitcoin nearing all-time highs. The cannabis industry reacts positively to Biden's call for cannabis reform. Cathie Wood sells $13.15M worth of Coinbase shares, opting for Palantir stock instead. Tesla's Bitcoin investment yields a substantial unrealized profit. The S&P 500 surges to a new high, driven by tech giants and improved investor sentiment. Biden's economic policies and calls for cannabis reform mark significant political statements. Tesla faces a valuation drop and legal challenges, while the EV market sees competition from Rivian.

Portfolio Pulse from Akanksha Bakshi

March 08, 2024 | 1:12 pm

SENS

Senseonics Holdings announced that data from its Eversense Post Approval Study will be presented at the 17th International Conference on Advanced Technologies and Treatments for Diabetes. This presentation could highlight the effectiveness and safety of the Eversense device, potentially impacting the company's reputation and investor confidence.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 1:07 pm

DMTK

DermTech, Inc. (DMTK) announced the presentation of research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and the publication of new research in the Journal of Investigative Dermatology. These developments highlight the company's ongoing efforts in dermatological research and its commitment to advancing skin health technologies.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 1:06 pm

PLTR

Dan Ives of Wedbush Securities has raised the price target for Palantir Technologies Inc. (PLTR) from $30 to $35, citing the company's strong potential in AI applications. Ives highlighted Palantir's AI and data analytics platform as essential for U.S. enterprises, referring to it as the 'Messi of AI thesis.' This bullish adjustment is supported by recent field checks and the belief that Palantir will capture a significant share of the $1 trillion AI Global TAM. The company's stock rose by 1.66% in premarket trading to $26.90. Additionally, Palantir has secured a $178 million contract extension from the U.S. Army for the development of advanced AI/ML technologies.

Portfolio Pulse from Benzinga Neuro

March 08, 2024 | 12:48 pm